A Randomized, Sponsor-Open, Investigator-Blinded, Subject-Blinded, Placebo-Controlled, Single-Ascending Dose (SAD) and Multiple-Ascending Dose (MAD) Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7049389 in Healthy Chinese Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2019
Price : $35 *
At a glance
- Drugs RO 7049389 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Roche
- 31 May 2019 Status changed from recruiting to completed.
- 04 Feb 2019 Planned End Date changed from 16 Jan 2019 to 1 May 2019.
- 04 Feb 2019 Planned primary completion date changed from 16 Jan 2019 to 1 May 2019.